Sotac Pharmaceuticals

Sotac Pharmaceuticals EPS CAGR 5Y

The EPS CAGR (5 Year) of Sotac Pharmaceuticals (SOTAC.NS) as of Nov 5, 2026 is 146.88 %.

EPS CAGR 5Y

146.88 %

Last updated:

EPS CAGR (5 Year) of Sotac Pharmaceuticals is 2025 146.88 % . EPS CAGR (5 Year) of Sotac Pharmaceuticals was 2024 - . It decreases by % lower compared to the previous year.

The Sotac Pharmaceuticals EPS CAGR 5Y history

The Sotac Pharmaceuticals EPS CAGR 5Y history
YEAREPS CAGR 5YYoY
146.88 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sotac Pharmaceuticals Stock analysis

What does Sotac Pharmaceuticals do? Sotac Pharmaceuticals Ltd develops and manufactures pharmaceutical products under loan license or contract manufacturing agreements for various marketers. The company specializes in Non Beta-Lactam tablets, capsules, syrup, and external preparations, with a therapeutic portfolio covering Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, Anti-Allergic, Derma Products, Antacid, Anti-Ulcerants, PPI, Anti-Emetics, Cardiac, Anti-Hypertensives, Analgesic, Anti-Pyretic, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics IP-Lactams and Non-IP-Lactams, Anti-Fungal, and Cephalosporin products. Its subsidiaries SOTAC Healthcare, SOTAC Research, and SOTAC Lifescience support its manufacturing and development activities. The company generates revenue by producing pharmaceutical products on a contract manufacturing basis for different marketers, who then market and sell these products under their own brands. Sotac Pharmaceuticals' manufacturing services are utilized by various marketers seeking to outsource production without maintaining their own facilities. The firm's focus on a diverse therapeutic portfolio ensures consistent demand across multiple healthcare segments. Sotac Pharmaceuticals' manufacturing capabilities are tailored to meet the specific requirements of its marketer clients, offering both Non Beta-Lactam and Beta-Lactam product lines. The company's subsidiaries provide additional support in healthcare, research, and lifescience sectors, enhancing its overall service offerings. Its product range spans from basic medications like Anti-Cold and Anti-Allergic to specialized treatments such as Anti-Fungal and Cephalosporin antibiotics. Sotac Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sotac Pharmaceuticals stock

EPS CAGR (5 Year) of Sotac Pharmaceuticals is 146.88 % in 2025.

On Eulerpool you can find the complete historical development of EPS CAGR (5 Year) Sotac Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The 5-year EPS CAGR measures compound per-share earnings growth over five years, providing a medium-term view of shareholder value creation.

To evaluate EPS CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS CAGR (5 Year).

EPS CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS CAGR (5 Year)'s Sotac Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Sotac Pharmaceuticals

All Key Metrics — Sotac Pharmaceuticals